Literature DB >> 28551500

Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.

Linda J Stephen1, Abbie Wishart2, Martin J Brodie2.   

Abstract

Psychiatric comorbidities are common in people with epilepsy. A retrospective study of characteristics associated with withdrawal due to psychiatric side effects was undertaken in patients with treated epilepsy participating in prospective audits with new antiepileptic drugs (AEDs). A total of 1058 treated patients with uncontrolled seizures (942 focal-onset seizures, 116 generalized genetic epilepsies [GGEs]) participated in eight prospective, observational audits from 1996 to 2014. These patients were prescribed adjunctive topiramate (n=170), levetiracetam (n=220), pregabalin (n=135), zonisamide (n=203), lacosamide (n=160), eslicarbazepine acetate (n=52), retigabine (n=64), or perampanel (n=54). Doses were titrated according to efficacy and tolerability to optimize zeizure outcomes and reduce side effects. Psychiatric comorbidities were recorded prior to and after the addition of each AED. At baseline, patients with focal-onset seizures (189 of 942; 20.1%) were statistically more likely to have psychiatric diagnoses compared to patients with GGEs (14 of 116, 12.1%; p=0.039). Following adjunctive AED treatment, neuropsychiatric adverse effects led to AED withdrawal in 1.9-16.7% of patients. Patients with a pre-treatment psychiatric history (22 of 209; 10.5%) were statistically more likely to discontinue their new AED due to psychiatric issues compared to patients with no previous psychiatric diagnosis (50 of 849; 5.9%; p=0.017). Patients receiving sodium channel blocking AEDs (4 of 212, 1.9%) were statistically less likely to develop intolerable psychiatric problems, compared to those on AEDs possessing other mechanisms of action (68 of 846, 8.0%; p=0.012). Depression was the commonest problem, leading to discontinuation of AEDs in 2.8% (n=30) patients. Aggression was statistically more common in men (11 of 527, 2.1%) compared to women (1 of 531, 0.2%; p=0.004). Patients with learning disability (12 of 122, 9.8%; p=0.0015) were statistically less likely to have psychiatric issues prior to adjunctive AED treatment compared to other patients (208 of 936, 22.2%), but there were no statistically significant differences once the new AEDs were added (8 of 122 patients with learning disability, 6.6%; 64 of 936 other patients, 6.8%). Awareness of these issues may assist clinicians in avoiding, identifying and treating psychiatric comorbidities in people with epilepsy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiepileptic drug; Epilepsy; Prospective audit; Psychiatric; Seizures; Side effects

Mesh:

Substances:

Year:  2017        PMID: 28551500     DOI: 10.1016/j.yebeh.2017.04.003

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  12 in total

Review 1.  Epilepsy and Psychiatric Comorbidities: Drug Selection.

Authors:  Marco Mula
Journal:  Curr Treat Options Neurol       Date:  2017-10-19       Impact factor: 3.598

Review 2.  Psychiatric Comorbidities in People With Epilepsy.

Authors:  Marco Mula; Andres M Kanner; Nathalie Jetté; Josemir W Sander
Journal:  Neurol Clin Pract       Date:  2021-04

3.  How do pediatric patients perceive adverse drug events of anticonvulsant drugs? A survey.

Authors:  Martina Patrizia Neininger; Sarah Woltermann; Sarah Jeschke; Birthe Herziger; Ruth Melinda Müller; Wieland Kiess; Thilo Bertsche; Astrid Bertsche
Journal:  Eur J Pediatr       Date:  2020-03-11       Impact factor: 3.183

4.  Adjunctive lacosamide treatment for adult focal-onset epilepsy: focus on comorbid intellectual/developmental disorders and differing responses.

Authors:  Ebru Apaydın Doğan; Umuttan Doğan; Emine Genç; Çağla Erdoğan; Bülent Oğuz Genç
Journal:  Ther Clin Risk Manag       Date:  2018-08-02       Impact factor: 2.423

5.  Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Authors:  Zhan-Miao Yi; Cheng Wen; Ting Cai; Lu Xu; Xu-Li Zhong; Si-Yan Zhan; Suo-Di Zhai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-17       Impact factor: 2.570

6.  Common mental illness among epilepsy patients in Bahir Dar city, Ethiopia: A cross-sectional study.

Authors:  Minale Tareke; Minychil Birehanu; Desalegne Amare; Andargie Abate
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240

7.  Individual vulnerabilities to psychosis after antiepileptic drug administration.

Authors:  Nozomi Akanuma; Naoto Adachi; Peter Fenwick; Masumi Ito; Mitsutoshi Okazaki; Koichiro Hara; Ryouhei Ishii; Masanori Sekimoto; Masaaki Kato; Teiichi Onuma
Journal:  BMJ Neurol Open       Date:  2020-08-27

8.  Depression in patients with epilepsy: screening, diagnosis and management.

Authors:  Amina Chentouf
Journal:  Tunis Med       Date:  2021 Mai

9.  Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli.

Authors:  Francisco Sales; João Chaves; Rob McMurray; Rui Loureiro; Hélder Fernandes; Vicente Villanueva
Journal:  Acta Neurol Scand       Date:  2020-08-12       Impact factor: 3.209

10.  On the Digital Psychopharmacology of Valproic Acid in Mice.

Authors:  John Samuel Bass; Anney H Tuo; Linh T Ton; Miranda J Jankovic; Paarth K Kapadia; Catharina Schirmer; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2020-11-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.